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Atezolizumab with chemotherapy has shown improved progression-free and overall survival in patients with metastatic PD-L1 positive
triple negative breast cancer (TNBC). Atezolizumab with anthracycline- and taxane-based neoadjuvant chemotherapy has also shown
increased pathological complete response (pCR) rates in early TNBC. This trial evaluated neoadjuvant carboplatin and paclitaxel with or
without atezolizumab in patients with clinical stages II-III TNBC. The co-primary objectives were to evaluate if chemotherapy and
atezolizumab increase pCR rate and tumor inﬁltrating lymphocyte (TIL) percentage compared to chemotherapy alone in the mITT
population. Sixty-seven patients (ages 25–78 years; median, 52 years) were randomly assigned – 22 patients to Arm A, and 45 to Arm B.
Median follow up was 6.6 months. In the modiﬁed intent to treat population (all patients evaluable for the primary endpoints who
received at least one dose of combination therapy), the pCR rate was 18.8% (95% CI 4.0–45.6%) in Arm A, and 55.6% (95% CI 40.0–70.4%)
in Arm B (estimated treatment difference: 36.8%, 95% CI 8.5–56.6%; p = 0.018). Grade 3 or higher treatment-related adverse events
occurred in 62.5% of patients in Arm A, and 57.8% of patients in Arm B. One patient in Arm B died from recurrent disease during the
follow-up period. TIL percentage increased slightly from baseline to cycle 1 in both Arm A (mean ± SD: 0.6% ± 21.0%) and Arm B
(5.7% ± 15.8%) (p = 0.36). Patients with pCR had higher median TIL percentages (24.8%) than those with non-pCR (14.2%) (p = 0.02).
Although subgroup analyses were limited by the small sample size, PD-L1-positive patients treated with chemotherapy and atezolizumab
had a pCR rate of 75% (12/16). The addition of atezolizumab to neoadjuvant carboplatin and paclitaxel resulted in a statistically signiﬁcant
and clinically relevant increased pCR rate in patients with clinical stages II and III TNBC. (Funded by National Cancer Institute).
npj Breast Cancer (2022)8:134 ; https://doi.org/10.1038/s41523-022-00500-3

INTRODUCTION
Triple negative breast cancer (TNBC) represents approximately
10–20% of breast cancers and is deﬁned by a lack of expression
of the estrogen receptor (ER), progesterone receptor (PR), and
human epidermal growth factor receptor 2 (HER2) receptor1.
TNBC has a higher incidence in young black women and in
women with a deleterious mutation in the BRCA1 gene2,3.
Established targeted therapies in breast cancer, such as
tamoxifen and trastuzumab, are primarily directed against
nuclear or surface receptors. Despite neoadjuvant chemotherapy trials showing that TNBC has higher pathological complete
response (pCR) rates to chemotherapy compared to hormonereceptor-positive subtypes4, TNBC remains difﬁcult to treat due
to chemotherapy resistance, and many patients relapse within 5
years5. Patients with TNBC typically have a worse initial
prognosis compared to patients with other breast cancer
subtypes. Therefore, there is a signiﬁcant need to develop
new treatment strategies for TNBC.
Programmed death ligand 1 (PD-L1) expression is prevalent in
many human tumors, and its overexpression has been associated

with poor prognosis in patients with several cancers6–9. PD-L1
binds to two known inhibitory receptors expressed on activated
T cells (PD-1 and B7-1), and PD-L1 expression is sustained in states
of chronic stimulation such as cancer10,11. Aberrant expression of
PD-L1 impedes anti-tumor immunity, resulting in immune
evasion12. Interruption of the PD-L1/PD-1 and PD-L1/B7.1 pathway
reinvigorates tumor-speciﬁc T-cell immunity. TNBC has characteristics that may be associated with improved response to immune
checkpoint inhibition, including increased mutational complexity13–16, higher PD-L1 expression17–21, and higher tumor inﬁltrating
lymphocytes (TIL) compared to other breast cancer subtypes22–25.
Atezolizumab is a human immunoglobulin (Ig) G1 monoclonal
antibody that targets PD-L1 and inhibits its interaction with its
receptors, PD-1 and B7-1. Atezolizumab is approved as a single-agent
or in combination with other therapy for the treatment of a variety of
advanced cancers, including TNBC26, urothelial27, lung28–30, and
hepatocellular31. In the IMpassion130 study, the addition of
atezolizumab to nab-paclitaxel improved progression-free survival
(PFS) and a clinically meaningful improvement in overall survival (OS)
in patients with metastatic PD-L1-positive TNBC26,32. The beneﬁt of
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Fig. 1 CONSORT diagram. Flow of patients randomly assigned in
NCI 10013.

immunotherapy in early stage TNBC is being explored in multiple
clinical trials. KEYNOTE-522 and IMpassion031 both demonstrated
statistically signiﬁcant improvements in pCR rates when checkpoint
inhibitors were added to chemotherapy versus chemotherapy
alone33,34. However, in the NeoTRIPaPDL1 trial, atezolizumab plus
chemotherapy did not signiﬁcantly improve pCR rates compared
with chemotherapy alone in patients with early stage high-risk or
locally advanced TNBC35. It should be noted that the chemotherapy
backbone was carboplatin + nab-paclitaxel, which is not conventional, and the study’s endpoint was event free survival (EFS) and not
pCR. Herein, we present the results of the NCI-10013 study
(clinicaltrials.gov number, NCT02883062), conducted to evaluate
the addition of atezolizumab to non-anthracycline-based neoadjuvant chemotherapy in patients with clinical stages II and III TNBC.
RESULTS
Patient characteristics
From August 2017 to September 2019, 67 patients from 9 sites
were randomly assigned in a 1:2 fashion to either Arm A (22
patients) or Arm B (45 patients). Six patients randomized to Arm A
withdrew consent; only 2 of these received protocol therapy and
withdrew consent during treatment (Fig. 1). These 2 patients are
excluded from the mITT analyses as further data collection did not
occur on them due to withdrawal of consent, and they are deemed
not evaluable because deﬁnitive pathology reports are not
available. Median follow up is 6.6 months (range 0.3–15.6 months).
The patients’ characteristics are shown in Table 1. Median age is 52
years (range 25–78); 54 years in Arm A and 49 years in Arm B.
Overall, forty-three (64.2%) were Caucasian and thirteen (19.4%)
were African American. Twenty-ﬁve (37.3%) were pre-menopausal.
67.2% and 32.8% had stages II and III disease respectively. Nine
(13.4%) had a known germline mutation in either BRCA1 or BRCA2.
Genetic testing was according to institutional practices and was
not protocol mandated. 54.5% of patients were PD-L1-negative as
assessed using the VENTANA PD-L1 (SP142) assay.
Efﬁcacy
In the mITT population, 3 of 16 patients achieved pCR in Arm A 18.8% (95% CI 4.0–45.6%), versus 25 of 45 patients in Arm B 55.6% (95% CI 40.0–70.4%); estimated treatment difference, 36.8
percentage points; p value 0.018 (logistic regression, Fig. 2). pCR in
those with BRCA mutations was 50% (2/4) and 80% (4/5) in Arm A
and Arm B, respectively.
Safety
All patients who received at least 1 cycle of combination
chemotherapy were evaluable for toxicity. Treatment delays were
observed in 9 patients (40.9%) in Arm A, and 20 (44.4%) in Arm B.
npj Breast Cancer (2022) 134

Baseline patient characteristicsa.

Characteristic

Arm A, N = 22 (%)

Arm B, N = 45 (%)

p-values

Median age
Menopausal status
Premenopausal
Postmenopausal
Unknown
ECOGc
0
1
Race
White
African American
Other
Clinical stage
II
III
Nodal involvement
Positive
Negative
Unknown
Germline BRCA status
Wild type
Mutant
Unknown
Baseline PD-L1 status
Negative
Positive
Unknown

54

49

5 (22.7)
14 (63.6)
3 (13.6)

20 (44.4)
24 (53.3)
1 (2.2)

0.43
0.07
(0.17)b

21 (95.5)
1 (4.5)

41 (91.1)
4 (8.9)

16 (72.7)
2 (9.1)
4 (18.2)

27 (60.0)
11 (24.4)
7 (15.6)

14 (63.6)
8 (36.4)

31 (68.9)
14 (31.1)

11 (50.0)
9 (40.1)
2 (9.1)

21 (46.7)
24 (53.3)
0 (0.0)

13 (59.1)
4 (18.2)
5 (22.7)

34 (75.6)
5 (11.1)
6 (13.3)

5 (22.7)
4 (18.2)
13 (59.1)

19 (42.2)
16 (35.6)
10 (22.2)

>0.99
0.37

0.78

0.12
(0.60)b

0.40
(0.43)b

0.015
(>0.99)b

a

Data are shown for the intent to treat population.
Excluding patients with unknown status.
c
Eastern Cooperative Oncology Group (ECOG) performance status.
b

Dose reductions occurred in 4 patients (18.1%) in Arm A, and in 6
(13.3%) in Arm B. Grade 3 or higher treatment-related adverse
events occurred in 62.5% of patients in Arm A and 57.8% of patients
in Arm B (Table 2). The incidence of grade 3/4 anemia was 12.5% in
Arm A versus 17.8% in Arm B; neutropenia was 43.8% in Arm A and
33.3% in Arm B. One patient in Arm B had grade 3 adrenal
insufﬁciency. No other immune-related adverse events occurred.
Four patients (25%) in Arm A and 10 (22.2%) in Arm B had at least
one serious adverse event, deﬁned as any death, life-threatening
adverse event, inpatient or prolonged existing hospitalization for
≥24 h, persistent or signiﬁcant incapacity or substantial disruption of
the ability to conduct normal life functions, congenital anomaly/
birth defect, or other experience which may jeopardize the subject
and may require medical or surgical intervention to prevent one of
the afore-mentioned outcomes. No treatment-related deaths
occurred, however, one patient in Arm B died from recurrent
disease during the follow-up period.
TIL analyses
TIL percentage is associated with response to adjuvant and
neoadjuvant chemotherapy in TNBC36. An increase in TIL
percentage in response to treatment is also associated with
pCR36 and response to immune checkpoint inhibition. One of
this study’s primary endpoints was to determine whether antiPD-L1 therapy increases TIL percentage. Forty-eight of 67
participants (71.6%, 13 in Arm A; 35 in Arm B) had tumor
specimens with cellularity sufﬁcient for TIL analyses. Other
Published in partnership with the Breast Cancer Research Foundation
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Fig. 2 Pathological complete response according to study arm. Arm A (orange bar) represents patients randomly assigned to chemotherapy
alone, Arm B (blue bar) represents patients assigned to atezolizumab plus chemotherapy. Error bars represent the 95% conﬁdence interval of
pCR rate.

cases could not be assessed for TIL percentage due to the
absence of invasive tumor, absence of peritumoral stroma, or
due to complete tissue necrosis. We believe that sampling error
(rather than response to therapy) is the most likely explanation
for the lack of tumor in these samples. Paired tumor samples
(taken at baseline, and between days 18–22 following cycle 1 of
therapy) for TIL analyses were available on 37 participants
(55.2%, 13 in Arm A; 24 in Arm B). Baseline TIL of <50% was
observed in 82.6% of all cases (75.0% and 88.5% of pCR and
non-pCR cases, respectively). Figure 3 provides examples of
representative cases with high and low TIL percentages.
In Arm A, there was no difference in TIL percentage following
treatment when comparing biopsies obtained at baseline and
post cycle 1 (GEE; p = 0.36): the median TIL percentage at baseline
was 16.7% (range 2.5–75.0%), while the median TIL percentage
post cycle 1 was 18.3% (range 8.3–50.0%) (estimated mean
change in those with paired samples: 0.5%, 95% CI −13.6% 14.7%). Similarly in Arm B, the administration of atezolizumab did
not lead to an increase in TIL percentage (GEE; p = 0.72): the
median TIL percentage at baseline was 17.5% (range 0–80.0%),
while the median TIL percentage post cycle 1 was 21.7% (range
3.3–50.0%) (estimated mean change in those with paired samples:
5.7%, 95% CI −1.4% - 12.9%) (Fig. 4A). The change over time
between Arms A and B was also not signiﬁcant (GEE; p = 0.36).
Among the 48 patients with TIL results, pCR rates in Arms A and
B were 7.7% and 54.3%, respectively. Evaluating all TIL data by
using methods for repeated measurements, patients who
achieved pCR had higher median TIL percentages (24.8%) than
those with residual disease (14.2%) (GEE; p = 0.02) (Fig. 4B).
Evaluating TIL at baseline only, there was a trend toward higher
median TIL percentages in patients who achieved pCR (23.1%)
versus those with residual disease (13.1%) (GEE; p = 0.08).

Published in partnership with the Breast Cancer Research Foundation

PD-L1 analyses
To assess PD-L1 expression two assays were utilized. First, PD-L1
expression was evaluated using the VENTANA PD-L1 (SP142) assay37.
This assay was performed by a CLIA-certiﬁed laboratory. A multiplex
immunoﬂuorescence assay (mIF) panel was also performed including PD-1, PD-L1, Pan Cytokeratin, CD8, and FOXP3.
When we assessed PD-L1 status using the VENTANA PD-L1
(SP142) assay, we observed numerically improved response rates
with chemotherapy plus atezolizumab in both PD-L1-negative and
PD-L1-positive patients. The pCR rate was 20% (1/5) vs. 31.6% (6/
19) in PD-L1-negative patients, and 0% (0/4) vs 75% (12/16) in PDL1-positive patients (logistic regression; p > 0.99 and p = 0.01,
respectively) in arm A vs. arm B, respectively. (Fig. 5A).
When we assessed PD-L1 status using mIF analyses, we
observed similar results. For these analyses, we used clone
E1L3N to assess PD-L1 expression. PD-L1 expression was
quantiﬁed based on count density (cells/mm2). For data analysis,
we used a cutoff of ≥1% cytokeratin-negative, PD-L1-positive cells.
This is the best approximation of the VENTANA PD-L1 (SP142)
assay cutoff of ≥1% immune cells. Based on this analysis, the pCR
rate was 25% (1/4) vs 25% (1/4) in PD-L1-negative patients, and
0% (0/3) vs 72% (13/18) in PD-L1-positive patients (logistic
regression; p > 0.99 and p = 0.04, respectively) (Fig. 5B).
Additional TIL correlative analyses were conducted to compare
TIL percentages by PD-L1 status. We compared baseline TIL
percentage in PD-L1-negative and PD-L1-positive patients by
SP142. We found that PD-L1-positive patients have a statistically
signiﬁcant higher TIL percentage. The median TIL percentage was
12.5% in PD-L1-negative patients and 33.1% in PD-L1-positive
patients (GEE; p = 0.006). In PD-L1-negative patients, there was a
statistically signiﬁcant difference in TIL percentage between
patients with residual disease and pCR (median TIL 8.3% vs.
20.2%; p = 0.03; GEE). In PD-L1-positive patients, there was no
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Adverse events.

Grade 3/4 AEs

Arm A, N = 16 (%)

Arm B, N = 45 (%)

Adrenal insufﬁciency
ALT increase
Anemia
Anorectal infection
Arthralgia
AST increase
Diarrhea
Gastroesophageal reﬂux disease
Glucose intolerance
Eye inﬂammation
Hypocalcemia
Hypokalemia
Hypertension
Nausea
Neutropenia
Thrombocytopenia
Rash
Scleral disorder
Sepsis
Skin abscess
Syncope
Vomiting
Leucopenia
Patients with any SAEs
SAEs
ALT increase
Anemia
Anorectal infection
Arthralgia
AST increase
Diarrhea
Eye inﬂammation
Fatigue
Febrile neutropenia
Fever
Fracture
Hyperglycemia
Hypocalcemia
Nausea
Neutropenia
Rash
Sepsis
Syncope
Ventricular tachycardia
Vomiting

0
0
2
0
1
0
0
0
0
1
1
0
0
0
7
1
2
0
0
0
1
0
0
4

(0.0)
(0.0)
(12.5)
(0.0)
(6.3)
(0.0)
(0.0)
(0.0)
(0.0)
(6.3)
(6.3)
(0.0)
(0.0)
(0.0)
(43.8)
(6.3)
(12.6)
(0.0)
(0.0)
(0.0)
(6.3)
(0.0)
(0.0)
(25.0)

1 (2.2)
2 (4.40
8 (17.8)
1 (2.2)
0 (0.0)
1 (2.2)
1 (2.2)
1 (2.2)
1 (2.2)
0 (0.0)
0 (0.0)
1 (2.2)
1 (2.2)
1 (2.2)
15 (33.3)
0 (0.0)
1 (2.2)
1 (2.2)
1 (2.2)
2 (4.4)
1 (2.2)
1 (2.2)
1 (2.2)
10 (22.2)

0
0
0
1
0
0
1
0
0
0
0
0
1
0
1
0
0
0
0
0

(0.0)
(0.0)
(0.0)
(6.3)
(0.0)
(0.0)
(6.3)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(6.3)
(0.0)
(6.3)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)

1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
1
1
2
1
1

(2.2)
(2.2)
(2.2)
(2.2)
(2.2)
(2.2)
(2.2)
(2.2)
(2.2)
(2.2)
(2.2)
(2.2)
(2.2)
(2.2)
(4.4)
(2.2)
(2.2)
(4.4)
(2.2)
(2.2)

Bold entries highlight SAEs, as separate from all grade 3/4 AEs.

statistically signiﬁcant difference in TIL percentage between
patients with residual disease and pCR (median TIL 33.8% vs.
28.8%; p = 0.66; GEE) (Table 3).
Multiplex Immunoﬂuorescence
Multiplex immunoﬂuorescence (mIF) data were analyzed using
the mean cell density (cells/mm2). After performing PD-L1
(E1L3N) analysis, we assessed the remaining markers PD-1,
Cytokeratin (CTYOK), CD8, and Foxhead Box P3 (FOXP3). The
npj Breast Cancer (2022) 134

data demonstrated no statistically signiﬁcant difference between
the abundance of T- cells (CD8+), CD8+PD-1+ cells, and
T-regulatory cells (FOXP3) between patients with a pathological
complete response and non-pathological complete response in
Arm B, p = 0.25, p = 0.33, p = 0.48 (generalized linear regression
with negative binomial distribution) respectively as shown in
Supplementary Fig. 1.
Subgroup analyses
We performed analyses to evaluate for any potential association
between menopausal status and pCR, as well as nodal status and
pCR. In the pre-menopausal patients, the pCR rates in Arms A and B
were 66.7% (2/3) and 65% (13/20), respectively, and the difference
was not signiﬁcant (logistic regression; p = 0.95). In the postmenopausal patients, the pCR rates in Arms A and B were 8.3% (1/
12) and 45.8% (11/24), respectively, and there was a trend toward
signiﬁcant difference (logistic regression; p = 0.059) (Supplementary
Fig. 2). In the patients with negative lymph node at baseline, the pCR
rates in Arms A and B were 25% (2/8) and 54.2% (13/24),
respectively, and the difference was not signiﬁcant (logistic
regression; p = 0.21) In the patients with positive lymph node at
baseline, the pCR rates in Arms A and B were 12.5% (1/8) and 57.1%
(12/21), respectively, and there was a trend toward signiﬁcant
difference (logistic regression; p = 0.072) (Supplementary Fig. 3).
DISCUSSION
In this randomized open label phase 2 trial, patients with previously
untreated early stage TNBC who received neoadjuvant atezolizumab
plus chemotherapy achieved a statistically signiﬁcantly higher pCR
rate than those treated with chemotherapy alone. We used an
anthracycline-free platinum-based neoadjuvant backbone consisting
of carboplatin and paclitaxel. Platinum-taxane chemotherapy with
PD-L1 and/or PD-1 inhibition has been shown to be safe in trials in
different tumor types. Anthracyclines are associated with increased
cardiac toxicity, myelodysplastic syndromes, and treatment-related
leukemia38,39. Previous studies have shown that non-anthracycline
based regimens in patients with TNBC achieve similar pCR rates as
anthracycline plus taxane based regimens40–43. Although cross-trial
comparisons may be confounded by differences in trial characteristics, the high pCR rate observed in the anthracycline-free
experimental arm of this study is similar to rates observed in other
neoadjuvant trials utilizing anthracyclines, taxanes, and carboplatin
in TNBC44,45. Therefore, further studies evaluating non-anthracyclinebased chemoimmunotherapy regimens as an alternative strategy in
early TNBC are warranted.
During the conduct of this study, several other neoadjuvant trials
with immunotherapy in early TNBC were presented. The results of
the present trial are similar to results from KEYNOTE-522, which
evaluated checkpoint inhibition with pembrolizumab and
anthracycline-taxane and carboplatin based neoadjuvant chemotherapy in TNBC33 KEYNOTE-522 randomly assigned patients
with early stage TNBC to receive neoadjuvant therapy with four
cycles of carboplatin and paclitaxel, followed by four cycles of
doxorubicin or epirubicin with or without pembrolizumab. The pCR
rate in the pembrolizumab group was 63% (95% CI: 59–66%) and
56% (95% CI: 51–61%) in the placebo group46 (updated results
from FDA press release dated 7/26/21). Similarly, IMpassion031
demonstrated a higher pCR rate in patients with TNBC who
received neoadjuvant atezolizumab with nab-paclitaxel followed
by ddAC (58%, 95% CI 50–65%) versus those randomized to
placebo with chemotherapy (41%, 95% CI 34–49%) (p = 0.0044)34.
Conversely, the phase 3 NeoTRIPaPDL1 study evaluating atezolizumab with carboplatin and nab-paclitaxel did not lead to an
increase in pCR rates compared with carboplatin and nabpaclitaxel alone (43.5% with atezolizumab versus 40.8% with
chemotherapy alone, OR 1.11 [95% CI 0.69–1.79])35. pCR was a
Published in partnership with the Breast Cancer Research Foundation
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Fig. 3 Representative H&E sections demonstrating TIL percentage in breast cancer specimens. a Low TIL (5%). b high TIL (80%). Scale bar,
100 μm.

secondary endpoint in NeoTRIPaPDL1 and was reported prior to
event free survival results, the primary trial endpoint. A notable
difference in our trial and NeoTRIPaPDL1, is that NeoTRIPaPDL1
accrued patients who appeared to be higher risk (87% clinically
node positive) than the current trial population (48% clinically
node positive), although the subgroup analysis in Supplementary
Fig. 3 demonstrates no signiﬁcant difference in pCR rates between
lymph node-positive and negative patients. In addition, the
carboplatin was administered at a higher 3-weekly dosing schedule
in this trial, versus a lower weekly schedule in NeoTRIPaPDL1.
The pCR rate in the chemotherapy arm in this study is lower
than that reported in the literature for other recent studies of
platinum-based anthracycline-free neoadjuvant chemotherapy for
early TNBC. After careful review of the literature, we identiﬁed
three recent trials in patients with TNBC who were treated with
carboplatin and taxane-based neoadjuvant chemotherapy regimens. These studies provide additional information about the
expected pCR rate for the patients treated with chemotherapy
alone in this study. Sharma et al. reported the results of two
independent and separate prospective cohorts of patients with
stages I-III TNBC treated with six cycles of carboplatin and
docetaxel (NCT02302742 and NCT01560663)40. The pCR rate was
55% (95% CI: 48–62%) in 183 evaluable patients40. Additionally,
Ademuyiwa et al. reported the results of a prospective single
institution cohort that included 127 patients with clinical stages IIIII TNBC who received also received six cycles of docetaxel and
carboplatin (NCT02124902). This study had a pCR rate of 45.7%
(95% CI 36.9–54.7%)47. The NeoTRIPaPDL1 study discussed above
reported a pCR rate of 40.8% in the chemotherapy alone arm.
These studies demonstrate a range of pCR rates from 40-56%.
There are signiﬁcant differences between the trials reviewed and
the current trial being reported here. One of the most important
differences is the dose of chemotherapy, and the number of cycles
administered. A second important difference is the disease stage
of the patients included in the trials. It is plausible that the pCR
rate associated with neoadjuvant carboplatin plus taxane chemotherapy regimens is dose dependent. The comparative underperformance of this trial may be due to the less aggressive
chemotherapy regimen. It is notable that the current trial used
four cycles of carboplatin while similar trials used six cycles of
carboplatin (NCT02302742, NCT01560663, and NCT02124902). Our
trial also enrolled stage II-III patients, whereas the trials reported
by Sharma et al. enrolled stage I-III patients (NCT02302742,
NCT01560663). Based on the small number of evaluable patients
in our chemotherapy alone arm and these other considerations,
we are not surprised that the pCR rate in the neoadjuvant
chemotherapy alone arm was <40%.
Published in partnership with the Breast Cancer Research Foundation

Although pCR is a surrogate for long term outcomes in TNBC4,48,
the beneﬁt of immunotherapy in metastatic TNBC is modest in
response endpoints but more substantial in longer term clinical
outcomes. In the ITT population in IMpassion130, the difference in
objective response rates between those who received atezolizumab and those who did not was only 10.1%26. In the PD-L1positive population, the absolute median PFS improvement was
2.2 months with atezolizumab and chemotherapy relative to
chemotherapy alone, whereas ﬁnal overall survival analysis in the
PD-L1 positive patients showed a numerical improvement in
median OS of 7.5 months26,32,49. This phenomenon has also been
observed in other advanced cancers. For example, in non-small
cell lung cancer KEYNOTE-189 showed an absolute median PFS
improvement of 3.9 months with pembrolizumab added chemotherapy relative to chemotherapy alone, while the median OS
was not reached in the pembrolizumab group and was
11.3 months in the chemotherapy alone group50. Therefore, it is
possible that follow up data from this present trial and
NeoTRIPaPDL1 may translate into beneﬁcial long term efﬁcacy.
The addition of atezolizumab to platinum-based chemotherapy
was not associated with an increase in adverse events or dose
modiﬁcations. There were very few grade 3 and 4 events, with the
exception of anemia and neutropenia which are both consistent
with the well-established safety proﬁle of platinum-based neoadjuvant chemotherapy. The incidence of serious adverse events was
also similar in both study groups and no new safety signals were
identiﬁed. Immune-related adverse events can be permanent, and
associated with the requirement for long term hormone replacement therapy51,52. During this limited exposure to atezolizumab,
adrenal insufﬁciency was the only immune-related adverse event
observed in one patient in the atezolizumab arm.
We conducted analyses of the immune biomarker PD-L1. In
subgroup analyses using two different strategies to assess PD-L1
status, we observed numerically improved response rates with
chemotherapy plus atezolizumab in both PD-L1-negative and PDL1-positive patients. The improved response rates were statistically
signiﬁcant for PD-L1-positive patients. Of particular note, we
observed that PD-L1-positive patients treated with chemotherapy
plus atezolizumab had very high response rates (75% pCR rate).
Our ﬁndings are best interpreted in the context of several recently
reported studies. First, in the neoadjuvant setting, several studies
have demonstrated that PD-L1-positive patients have improved
response rates to both chemotherapy alone, and chemotherapy
plus atezolizumab. Second, in the neoadjuvant setting, both PD-L1positive and PD-L1-negative patients appear to derive a beneﬁt
from anti-PD-L1 therapy. By contrast, in patients with metastatic
TNBC, PD-L1-positive patients have a trend towards shorter PFS
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Fig. 4 TIL analyses. Boxplots of logarithm transformed TIL (%) by pCR status (a) and treatment arm (b), where the box stands for the
interquartile range, the bar inside a box represents the median, and the whiskers represent the whiskers represent 5th and 95th percentiles.

and overall survival compared to PD-L1-negative patients when
treated with chemotherapy alone, and only PD-L1-positive patients
beneﬁt from anti-PD-L1 therapy32,33. Reasons for the differences in
the predictive and prognostic impact of PD-L1 status according to
disease stage are unclear, but may represent differences in antitumor immunity and immune microenvironment by stage.
In the analysis of the remaining mIF markers we compared the
mean cell densities (cells/mm2) of T- cells (CD8+), CD8+PD-1+
cells, and T-regulatory cells (FOXP3) cell populations between
patients with a pathological complete response and nonpathological complete response in Arm B. There was no
statistically signiﬁcant difference between the abundance of these
cell populations in our subgroup analysis.
Immune cells are a deﬁning factor in tumor progression and
metastasis, and during phases of the immunoediting process,
immune cells may serve different roles in tumor progression53,54. Understanding the relationship between the TNBC
tumor immune microenvironment and beneﬁt of immunotherapy may help inform which combination strategies are most
appropriate for which group of patients with TNBC. Consistent
with prior studies25,55,56, we found that patients who achieved
pCR had higher TIL percentages than patients with residual
disease. Although atezolizumab did not signiﬁcantly increase
TIL percentage in general, there was a trend of a larger
difference in TIL percentages in pCR patients (almost all from
Arm B) versus non-pCR patients after cycle 1 versus at baseline
npj Breast Cancer (2022) 134

suggesting that atezolizumab may have increased TIL in
responding patients. More studies will need to clarify if
amplifying TIL with checkpoint inhibitors will lead to clinical
beneﬁt in patients with TNBC.
Strengths of this study include the high proportion of African
Americans accrued, which is likely reﬂective of the sites
included and the commitment of the investigators to accrue
minorities. Furthermore, this was a multicenter collaborative
study which simultaneously served as a platform for biomarker
analyses. Study limitations include the signiﬁcant number of
patients in the control arm who withdrew consent due to open
label design of this study. The selective dropout from Arm A
does not appear to have introduced any selection bias as the
baseline patient characteristics are equally distributed between
the Arms as documented in Table 1.
In conclusion, among patients with early stage TNBC, the
proportion who achieved pCR was statistically signiﬁcantly higher
among those who received neoadjuvant atezolizumab plus
chemotherapy than among those who received neoadjuvant
chemotherapy alone. Non-anthracycline-based chemotherapy
plus immunotherapy may be an alternative option for the
management of patients with early stage TNBC. The long-term
results of this trial and several other randomized trials will
together shape the landscape of checkpoint inhibition in the
management of early stage TNBC.
Published in partnership with the Breast Cancer Research Foundation

F.O. Ademuyiwa et al.

7
a

b
100

Pathological complete response (%)

Pathological complete response (%)

100

80

60

40

20

80

60

40

20

0

0

PD-L1-negative
chemotherapy
alone

PD-L1-negative
chemotherapy
plus atezolizumab

PD-L1-positive
chemotherapy
alone

PD-L1-positive
chemotherapy
plus atezolizumab

PD-L1-negative
chemotherapy
alone

PD-L1-negative
chemotherapy
plus atezolizumab

PD-L1-positive
chemotherapy
alone

PD-L1-positive
chemotherapy
plus atezolizumab
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METHODS
Patient eligibility
Eligible women had newly diagnosed untreated TNBC, deﬁned as ER
and PR < Allred score of 3 or ≤5% positive staining cells in the
invasive component of the tumor. HER2 negative disease was
deﬁned as negative by FISH or IHC staining 0 or 1+ according to the
American Society of Clinical Oncology and the College of American
Pathologists guidelines57. Patients had clinical stage T2-T4c, any N,
M0 primary tumor by AJCC 7th edition clinical staging. Other key
eligibility requirements were age ≥18 years, Eastern Cooperative
Oncology Group (ECOG) performance status of ≤2, adequate organ
function, and willingness and ability to provide informed consent.
Patients with contralateral breast cancer, a history of autoimmune
disease, uncontrolled intercurrent illness, or treatment with immunosuppressive medications were excluded.
Study design
The study was approved by the National Cancer Institute (NCI)
Central Institutional Review
Board (IRB) and each of the following independent ethics
committees: University Health Network Princess Margaret
Cancer Center Research Ethics Board, City of Hope Comprehensive Cancer Center IRB, Yale School of Medicine IRB and Human
Investigations Committee, Dana- Farber Cancer Institute single
IRB, The Sidney Kimmel Comprehensive Cancer Center at Johns
Hopkins Clinical Research Review Committee, The Mayo Clinic
IRB, Rutgers Cancer Institute of New Jersey IRB, The Ohio State
University Ofﬁce of Responsible Research Practices and IRB,
University of Pittsburgh Cancer Institute Research Ethics
Advisory Board and IRB, University of Texas MD Anderson
Cancer Center IRB, Duke University Health System, University of
California Davis Comprehensive Cancer Center IRB, and
Washington University IRB. The study was performed in
accordance with the International Conference on Harmonization
guidelines concerning Good Clinical Practice and the Declaration of Helsinki. ClinicalTrials.gov number is NCT02883062 and
Published in partnership with the Breast Cancer Research Foundation

registration date was August 29, 2016. All patients provided
written informed consent. Patients were recruited from nine
sites within the NCI Experimental Therapeutics Clinical Trials
Network (ETCTN) to this open-label phase 2 study (Washington
University School of Medicine, Mayo Clinic Arizona, Mayo Clinic
Florida, Ohio State University, UC Davis, University of Pittsburgh,
University of North Carolina, Duke University, and Johns Hopkins
University). The study design is shown in Fig. 6. All eligible
patients were randomly assigned, in a 1:2 ratio to the control
arm with carboplatin AUC5 every 3 weeks ×4 cycles plus
paclitaxel 80 mg/m2 every week ×12 weeks (Arm A), or the
investigational arm with carboplatin AUC5 every 3 weeks ×4
cycles plus paclitaxel 80 mg/m2 every week ×12 weeks plus
atezolizumab 1200 mg every 3 weeks ×4 cycles (Arm B).
Atezolizumab was provided by the Cancer Therapy Evaluation
Program (CTEP) as an investigational drug. Randomization was
centralized using the Interactive Web Response System (IWRS).
Patients were stratiﬁed according to clinical stage (II versus III).
Deﬁnitive surgery was 3–6 weeks following the completion of
neoadjuvant chemotherapy. All patients received dose-dense
AC (ddAC) administered in the adjuvant setting as per routine
care. ddAC consists of doxorubicin 60 mg/m2 on day 1 of each
2-week cycle plus cyclophosphamide 600 mg/m2 on day 1 of
each 2-week cycle ×4 cycles. Patients who underwent breast
conservation therapy (BCT) received adjuvant radiation according to institutional practices. Patients were followed for one year
after removal from study or until death, whichever occurred ﬁrst.
Research tumor biopsies for correlative studies were
obtained at baseline prior to chemotherapy, prior to cycle 2,
and at time of deﬁnitive surgery following neoadjuvant
chemotherapy in those patients with residual disease. Blood
for correlative studies was also collected (optional) at the same
time points.
TIL percentage assessment
TIL were quantiﬁed according to the method recommended by
the International Immuno-Oncology Biomarker Working Group
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Table 3.

Baseline TIL (%) by PD-L1 and pCR status (Arms A and B).
Residual disease (N = 24)

pCR (N = 17)

P-value*

P-value**

17

6

0.037

0.007

13.48

30.28

PD-L1 status

Covariate

Statistics

Negative

TIL%

N
Mean
Median

8.75

20.21

N

7

11

Mean

40.06

40.95

Median

33.75

28.75

Positive

TIL%

0.662

*p-value for non-pCR vs. pCR groups, stratiﬁed by PD-L1 status; **p-value for PD-L1-negative vs. PD-L1-positive.

on Breast Cancer58. Two subspecialized breast pathologists (IH,
ZL) independently reviewed whole slide scans (blinded to each
other, treatment status, and time point) and documented the
percentage of TIL inﬁltration in tumor-adjacent stroma, in
increments of 5%. Discrepancies of >10% points were adjudicated in a consensus conference setting. The mean of the two
observations, or the consensus determination if applicable, was
used for analysis.
PD-L1 immunohistochemistry
Evaluation of PD-L1 expression was performed at HistoGeneX
(now CellCarta NV) laboratory located in Naperville, IL USA
using the VENTANA SP142 IHC assay performed on the Ventana
BenchMark ULTRA Instrument (Ventana Medical Systems,
Tucson AZ) using the Optiview DAB IHC Detection system.
Immune inﬁltrate staining is scored as the area of PD-L1
positive immune inﬁltrating cells as a percentage of total
tumor area. Immune inﬁltrate cells include immune cells
showing PD-L1 staining (punctate staining as well as circumferential staining) that include lymphocytes, macrophages, and
cells with dendritic and reticular morphology. Tumor area is the
area occupied by tumor cells as well as their associated
intratumoral and contiguous peritumoral desmoplastic stroma.
Given the fact the immune cells are present not only within the
stroma, but also are seen as single cells or diffuse spread within
the tumor cells, tumor area is chosen as the denominator. The
fraction of viable Tumor Cells (TC) percentage that express PDL1 (discernible membrane staining of any intensity) can be
scored. Cytoplasmic staining is not included in the scoring. The
immune cell (IC) score is a relative area estimate percent of
tumor area that is covered by PD-L1-positive ICs. For the
purposes of this study a cutoff of ≥1% IC was considered
positive.
Multiplex immunoﬂuorescence
Multiplex immunoﬂuorescence (mIF) was performed using a
Bond RX fully automated stainer (Leica Biosystems, Inc.) on 5µm-thick FFPE (formalin-ﬁxed, parafﬁn-embedded) whole tissue
sections. Slides were baked for 3 h at 60 °C, loaded onto the
Bond RX, deparafﬁnized (BOND DeWax Solution, Leica Biosystems) and rehydrated with a graded ethanol series. Sequential
rounds of antigen retrieval, primary antibody incubation, and
OpalTM Fluorophore (Akoya Biosciences) incubation were
carried out as detailed in Table below, followed by staining
with
nuclear
counterstain/4′,6-diamidino-2-phenylindole
(DAPI). All slides were scanned at 20x resolution using a Vectra
Polaris imaging platform (Akoya Biosciences). Regions of
Interest (ROIs) were selected for each sample with pathologist
supervision (SJR). Images were segmented, phenotyped and
scored for each individual marker using InForm Image Analysis
software (Akoya Biosciences). A custom script was used to
extract the density and percentage of cells which are positive
npj Breast Cancer (2022) 134

for relevant biomarkers in speciﬁc tissue regions (tumor and
tumor-stroma interface).
Target

Antibody
clone #

Antigen
retrieval

Primary antibody Opal ﬂuorodilution
phore

FOXP3

D608R (Cell
Signaling)

ER 2,
40 min

1:100

570

PD-L1

E1L3N (Cell
Signaling)

ER 1,
20 min

1:300

520

Cytokeratin AE1/AE3
(Agilent)

ER 1,
20 min

1:100

690

PD-1

EPR4877
(Abcam)

ER 1,
20 min

1:300

620

CD8

4B11 (Leica)

ER 1,
20 min

1:200

480

Statistical analyses
The co-primary endpoints are pCR rate, and differences in TIL
percentage from baseline to after initiation of therapy (day 18–22).
pCR is deﬁned as absence of residual invasive cancer in the surgical
breast tissue and lymph node specimens. Other objectives included
assessing the safety of the combination of carboplatin plus paclitaxel
plus atezolizumab, evaluating potential biomarkers of response to
the combination, evaluating the impact of the combination on
immune response, and evaluating the impact of the combination on
overall survival (OS) and disease-free survival (DFS).
The study was designed to enroll 20 patients to Arm A and 40
patients to Arm B to provide 80% power at 1-sided alpha = 0.10 to
detect a minimum of 15% difference in TIL percentage, and 29%
improvement (69% versus 40%) in pCR. pCR results are presented
in the modiﬁed intention-to-treat (mITT) population, which
includes all randomized patients who were evaluable for the
primary endpoint and received at least one dose of combination
therapy. Patient demographics and clinical characteristics were
summarized using counts and frequencies for categorical
variables, or means and standard deviations for continuous
variables. The distributions of these baseline factors across arms
were compared using two-sample t-test, or Fisher’s exact test as
appropriate. The 95% exact binomial conﬁdence limits for pCR
was calculated in each arm. The difference in pCR rates between
two arms (overall and by subgroups) was described using
Miettinen-Nurminen conﬁdence intervals and compared by
univariate Firth logistic regression models. TIL percentage was
summarized as means, medians, and standard deviations at each
time point. The over-time changes and between-group differences
in TIL percentages were assessed using generalized estimating
equation (GEE) which is less sensitive to the assumption of
normality distribution. Natural logarithm transformation was also
performed in TIL percentages to reduce its right-skewing. All the
Published in partnership with the Breast Cancer Research Foundation
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Fig. 6 Clinical trial schema outlining treatment arm, randomization, collection of biopsies, and adjuvant treatment. AUC area under the
curve, dd dose dense.

statistical analyses were performed using SAS 9.4 (SAS Institutes,
Cary, NC).
Reporting summary
Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
DATA AVAILABILITY
The clinical and other assay data generated in this study will be made publicly
available in the NCI Clinical Trials Data Commons (CTDC) and Cancer Data Service
(CDS) components of the NCI’s Cancer Research Data Commons (CRDC). Access to
these repositories is available at the links below: https://datacommons.cancer.gov/
repository/clinical-trial-data-commons https://datacommons.cancer.gov/repository/
cancer-data-service#:~:text=The%20Cancer%20Data%20Service%20(CDS,generated
%20by%20NCI%20funded%20programs These repositories are being prepared to
receive the data and data-sharing logistics are being coordinated.

Received: 29 March 2021; Accepted: 13 December 2022;

REFERENCES
1. DeSantis, C. E. et al. Breast cancer statistics, 2019. CA Cancer J. Clin. 69, 438–451
(2019).
2. Huo, D. et al. Population differences in breast cancer: survey in indigenous
African women reveals over-representation of triple-negative breast cancer. J.
Clin. Oncol. 27, 4515–4521 (2009).
3. Gonzalez-Angulo, A. M. et al. Incidence and outcome of BRCA mutations in
unselected patients with triple receptor-negative breast cancer. Clin. Cancer Res.
17, 1082–1089 (2011).
4. Liedtke, C. et al. Response to neoadjuvant therapy and long-term survival in
patients with triple-negative breast cancer. J. Clin. Oncol. 26, 1275–1281 (2008).
5. Dent, R. et al. Triple-negative breast cancer: clinical features and patterns of
recurrence. Clin. Cancer Res. 13, 4429–4434 (2007).
6. Thompson, R. H. et al. Tumor B7-H1 is associated with poor prognosis in renal cell
carcinoma patients with long-term follow-up. Cancer Res. 66, 3381–3385 (2006).
7. Hamanishi, J. et al. Programmed cell death 1 ligand 1 and tumor-inﬁltrating
CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl
Acad. Sci. USA 104, 3360–3365 (2007).
8. Okazaki, T. & Honjo, T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 19, 813–824 (2007).
9. Hino, R. et al. Tumor cell expression of programmed cell death-1 ligand 1 is a
prognostic factor for malignant melanoma. Cancer 116, 1757–1766 (2010).
10. Blank, C., Gajewski, T. F. & Mackensen, A. Interaction of PD-L1 on tumor cells with
PD-1 on tumor-speciﬁc T cells as a mechanism of immune evasion: implications
for tumor immunotherapy. Cancer Immunol. Immunother. 54, 307–314 (2005).

Published in partnership with the Breast Cancer Research Foundation

11. Keir, M. E., Butte, M. J., Freeman, G. J. & Sharpe, A. H. PD-1 and its ligands in
tolerance and immunity. Annu Rev. Immunol. 26, 677–704 (2008).
12. Blank, C. & Mackensen, A. Contribution of the PD-L1/PD-1 pathway to T-cell
exhaustion: an update on implications for chronic infections and tumor evasion.
Cancer Immunol. Immunother. 56, 739–745 (2007).
13. Budczies, J. et al. Classical pathology and mutational load of breast cancer integration of two worlds. J. Pathol. Clin. Res. 1, 225–238 (2015).
14. Kandoth, C. et al. Mutational landscape and signiﬁcance across 12 major cancer
types. Nature 502, 333–339 (2013).
15. Liedtke, C., Bernemann, C., Kiesel, L. & Rody, A. Genomic proﬁling in triplenegative breast cancer. Breast Care 8, 408–413 (2013).
16. Shah, S. P. et al. The clonal and mutational evolution spectrum of primary triplenegative breast cancers. Nature 486, 395–399 (2012).
17. Ghebeh, H. et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is
expressed in breast cancer patients with inﬁltrating ductal carcinoma: correlation
with important high-risk prognostic factors. Neoplasia 8, 190–198 (2006).
18. Mittendorf, E. A. et al. PD-L1 expression in triple-negative breast cancer. Cancer
Immunol. Res. 2, 361–370 (2014).
19. Beckers, R. K. et al. Programmed death ligand 1 expression in triple-negative
breast cancer is associated with tumour-inﬁltrating lymphocytes and improved
outcome. Histopathology 69, 25–34 (2016).
20. Muenst, S. et al. Expression of programmed death ligand 1 (PD-L1) is associated with
poor prognosis in human breast cancer. Breast Cancer Res. Treat. 146, 15–24 (2014).
21. Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody
MPDL3280A in cancer patients. Nature 515, 563–567 (2014).
22. Loi, S. et al. Prognostic and predictive value of tumor-inﬁltrating lymphocytes in a
phase III randomized adjuvant breast cancer trial in node-positive breast cancer
comparing the addition of docetaxel to doxorubicin with doxorubicin-based
chemotherapy: BIG 02-98. J. Clin. Oncol. 31, 860–867 (2013).
23. Stanton, S. E., Adams, S. & Disis, M. L. Variation in the incidence and magnitude of
tumor-inﬁltrating lymphocytes in breast cancer subtypes: a systematic review.
JAMA Oncol. 2, 1354–1360 (2016).
24. Adams, S. et al. Prognostic value of tumor-inﬁltrating lymphocytes in triplenegative breast cancers from two phase III randomized adjuvant breast cancer
trials: ECOG 2197 and ECOG 1199. J. Clin. Oncol. 32, 2959–2966 (2014).
25. Denkert, C. et al. Tumor-inﬁltrating lymphocytes and response to neoadjuvant
chemotherapy with or without carboplatin in human epidermal growth factor
receptor 2-positive and triple-negative primary breast cancers. J. Clin. Oncol. 33,
983–991 (2015).
26. Schmid, P. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative
breast cancer. N. Engl. J. Med. 379, 2108–2121 (2018).
27. Balar, A. V. et al. Atezolizumab as ﬁrst-line treatment in cisplatin-ineligible
patients with locally advanced and metastatic urothelial carcinoma: a single-arm,
multicentre, phase 2 trial. Lancet 389, 67–76 (2017).
28. Horn, L. et al. First-line atezolizumab plus chemotherapy in extensive-stage smallcell lung cancer. N. Engl. J. Med. 379, 2220–2229 (2018).
29. Socinski, M. A. et al. Atezolizumab for ﬁrst-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378, 2288–2301 (2018).
30. West, H. et al. Atezolizumab in combination with carboplatin plus nabpaclitaxel chemotherapy compared with chemotherapy alone as ﬁrst-line
treatment for metastatic non-squamous non-small-cell lung cancer

npj Breast Cancer (2022) 134

F.O. Ademuyiwa et al.

10
31.
32.

33.
34.

35.

36.

37.

38.

39.

40.

41.

42.

43.

44.

45.

46.

47.

48.

49.

50.
51.

(IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet
Oncol. 20, 924–937 (2019).
Finn, R. S. et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular
Carcinoma. N. Engl. J. Med. 382, 1894–1905 (2020).
Schmid, P. et al. Atezolizumab plus nab-paclitaxel as ﬁrst-line treatment for
unresectable, locally advanced or metastatic triple-negative breast cancer
(IMpassion130): updated efﬁcacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 21, 44–59 (2020).
Schmid, P. et al. Pembrolizumab for early triple-negative breast cancer. N. Engl. J.
Med. 382, 810–821 (2020).
Mittendorf, E. A. et al. Neoadjuvant atezolizumab in combination with sequential
nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet 396, 1090–1100
(2020).
Gianni, L. et al. Pathologic complete response (pCR) to neoadjuvant treatment
with or without atezolizumab in triple-negative, early high-risk and locally
advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann. Oncol.
33, 534–543 (2022).
Gao, G., Wang, Z., Qu, X. & Zhang, Z. Prognostic value of tumor-inﬁltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and
meta-analysis. BMC Cancer 20, 179 (2020).
Roche.
https://www.accessdata.fda.gov/cdrh_docs/pdf16/p160002s009c.pdf?
msclkid=92ae59acd07211ec90db9b2646ed9dda,
https://www.accessdata.fda.
gov/cdrh_docs/pdf16/p160002s009c.pdf?msclkid=92ae59acd07211ec90db9b2
646ed9dda (2019).
Henderson, I. C. et al. Improved outcomes from adding sequential Paclitaxel but
not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for
patients with node-positive primary breast cancer. J. Clin. Oncol. 21, 976–983
(2003).
Early Breast Cancer Trialists’ Collaborative, G. et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of
long-term outcome among 100,000 women in 123 randomised trials. Lancet 379,
432–444 (2012).
Sharma, P. et al. Pathological response and survival in triple-negative breast
cancer following neoadjuvant carboplatin plus docetaxel. Clin. Cancer Res. 24,
5820–5829 (2018).
Sharma, P. et al. Efﬁcacy of neoadjuvant carboplatin plus docetaxel in triplenegative breast cancer: combined analysis of two cohorts. Clin. Cancer Res. 23,
649–657 (2017).
Kern, P. et al. Neoadjuvant, anthracycline-free chemotherapy with carboplatin
and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis
of rates of pathologic complete response and survival. J. Chemother. 28, 210–217
(2016).
Kern, P. et al. Neoadjuvant, anthracycline-free chemotherapy with carboplatin
and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis
of feasibility and rates of pathologic complete response. Chemotherapy 59,
387–394 (2013).
Sikov, W. M. et al. Impact of the addition of carboplatin and/or bevacizumab to
neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and
cyclophosphamide on pathologic complete response rates in stage II to III triplenegative breast cancer: CALGB 40603 (Alliance). J. Clin. Oncol. 33, 13–21 (2015).
von Minckwitz, G. et al. Neoadjuvant carboplatin in patients with triple-negative
and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase
2 trial. Lancet Oncol. 15, 747–756 (2014).
US Food and Drug Administration. FDA approves pembrolizumab for high-risk
early-stage triple-negative breast cancer, https://www.fda.gov/drugs/resourcesinformation-approved-drugs/fda-approves-pembrolizumab-high-risk-early-stagetriple-negative-breast-cancer (2021).
Ademuyiwa, F. O. et al. Immunogenomic proﬁling and pathological response
results from a clinical trial of docetaxel and carboplatin in triple-negative breast
cancer. Breast Cancer Res Treat. 189, 187–202 (2021).
von Minckwitz, G. et al. Deﬁnition and impact of pathologic complete response
on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer
subtypes. J. Clin. Oncol. 30, 1796–1804 (2012).
Emens, L. A. et al. IMpassion130: ﬁnal OS analysis from the pivotal Phase III study
of atezolizumab + nab paclitaxel vs placebo + nab paclitaxel in previously
untreated locally advanced or metastatic triple negative breast cancer. ESMO
2020 Virtual Congress.
Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell
lung cancer. N. Engl. J. Med. 378, 2078–2092 (2018).
Byun, D. J., Wolchok, J. D., Rosenberg, L. M. & Girotra, M. Cancer immunotherapy immune checkpoint blockade and associated endocrinopathies. Nat. Rev. Endocrinol. 13, 195–207 (2017).

npj Breast Cancer (2022) 134

52. Yoest, J. M. Clinical features, predictive correlates, and pathophysiology of
immune-related adverse events in immune checkpoint inhibitor treatments in
cancer: a short review. Immunotargets Ther. 6, 73–82 (2017).
53. Mittal, D., Gubin, M. M., Schreiber, R. D. & Smyth, M. J. New insights into cancer
immunoediting and its three component phases-elimination, equilibrium and
escape. Curr. Opin. Immunol. 27, 16–25 (2014).
54. Dunn, G. P., Old, L. J. & Schreiber, R. D. The three Es of cancer immunoediting.
Annu Rev. Immunol. 22, 329–360 (2004).
55. Ono, M. et al. Tumor-inﬁltrating lymphocytes are correlated with response to
neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res.
Treat. 132, 793–805 (2012).
56. Schmid, P. et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of
high-risk, early-stage triple-negative breast cancer: results from the phase 1b
open-label, multicohort KEYNOTE-173 study. Ann. Oncol. 31, 569–581 (2020).
57. Wolff, A. C. et al. Human epidermal growth factor receptor 2 testing in breast
cancer: American Society of Clinical Oncology/College of American Pathologists
clinical practice guideline focused update. J. Clin. Oncol. 36, 2105–2122 (2018).
58. Salgado, R. et al. The evaluation of tumor-inﬁltrating lymphocytes (TILs) in breast
cancer: recommendations by an International TILs Working Group 2014. Ann.
Oncol. 26, 259–271 (2015).

ACKNOWLEDGEMENTS
Acknowledgments of research support for the study: National Cancer Institute Cancer
Therapy Evaluation Program. We thank the Alvin J. Siteman Cancer Center at
Washington University School of Medicine and Barnes-Jewish Hospital in St. Louis,
MO. and the Institute of Clinical and Translational Sciences (ICTS) at Washington
University in St. Louis, for the use of the Tissue Procurement Core. The Siteman
Cancer Center is supported in part by an NCI Cancer Center Support Grant #P30
CA091842 and the ICTS is funded by the National Institutes of Health’s NCATS Clinical
and Translational Science Award (CTSA) program grant #UL1 TR002345. Scientiﬁc and
ﬁnancial support for the CIMAC-CIDC Network are provided through the National
Cancer Institute (NCI) Cooperative Agreements: U24CA224331 (to the Dana-Farber
Cancer Institute CIMAC) and U24CA224316 (to the CIDC at Dana-Farber Cancer
Institute). Additional support is made possible through the NCI CTIMS Contract
HHSN261201600002C (to the Emmes Company, LLC) This project was supported by
NCI grant number UM1CA186689. preliminary results from this study were presented
at the San Antonio Breast Cancer Symposium 2020.

AUTHOR CONTRIBUTIONS
F.O.A. made substantial contributions to the conception and design of the work, the
acquisition, analysis, interpretation of data; drafted the work and substantively revised it
AND approved the submitted version; AND has agreed both to be personally
accountable for the author’s own contributions and to ensure that questions related to
the accuracy or integrity of any part of the work, even ones in which the author was not
personally involved, are appropriately investigated, resolved, and the resolution
documented in the literature. F.G. made substantial contributions to the design of
the work, analysis, interpretation of data; drafted the work and substantively revised it
AND approved the submitted version; AND has agreed both to be personally
accountable for the author’s own contributions and to ensure that questions related to
the accuracy or integrity of any part of the work, even ones in which the author was not
personally involved, are appropriately investigated, resolved, and the resolution
documented in the literature. C.R.S. made substantial contributions the acquisition,
analysis, interpretation of data; drafted the work and substantively revised it AND
approved the submitted version; AND has agreed both to be personally accountable for
the author’s own contributions and to ensure that questions related to the accuracy or
integrity of any part of the work, even ones in which the author was not personally
involved, are appropriately investigated, resolved, and the resolution documented in
the literature. I.C. made substantial contributions to drafting the work and substantively
revised it AND approved the submitted version; AND has agreed both to be personally
accountable for the author’s own contributions and to ensure that questions related to
the accuracy or integrity of any part of the work, even ones in which the author was not
personally involved, are appropriately investigated, resolved, and the resolution
documented in the literature. D.W.N., R.W., M.A. and A.B. made substantial contributions
to the acquisition, analysis, interpretation of data; drafted the work and substantively
revised it AND approved the submitted version; AND has agreed both to be personally
accountable for the author’s own contributions and to ensure that questions related to
the accuracy or integrity of any part of the work, even ones in which the author was not
personally involved, are appropriately investigated, resolved, and the resolution
documented in the literature. E.C.D. made substantial contributions to the design of
the work, the acquisition, analysis, interpretation of data; drafted the work and
substantively revised it AND approved the submitted version; AND has agreed both to

Published in partnership with the Breast Cancer Research Foundation

F.O. Ademuyiwa et al.

11
be personally accountable for the author’s own contributions and to ensure that
questions related to the accuracy or integrity of any part of the work, even ones in
which the author was not personally involved, are appropriately investigated, resolved,
and the resolution documented in the literature. C.A.S.-M., R.M.C., J.F. and A.M.-A. made
substantial contributions to the acquisition, analysis, interpretation of data; drafted the
work and substantively revised it AND approved the submitted version; AND has agreed
both to be personally accountable for the author’s own contributions and to ensure that
questions related to the accuracy or integrity of any part of the work, even ones in
which the author was not personally involved, are appropriately investigated, resolved,
and the resolution documented in the literature. J.M.H., M.C. and S.R.D. made substantial
contributions to the analysis, interpretation of data; AND approved the submitted
version; AND has agreed both to be personally accountable for the author’s own
contributions and to ensure that questions related to the accuracy or integrity of any
part of the work, even ones in which the author was not personally involved, are
appropriately investigated, resolved, and the resolution documented in the literature.
S.L. made substantial contributions to the acquisition of data; AND approved the
submitted version; AND has agreed both to be personally accountable for the author’s
own contributions and to ensure that questions related to the accuracy or integrity of
any part of the work, even ones in which the author was not personally involved, are
appropriately investigated, resolved, and the resolution documented in the literature.
K.L.P. made substantial contributions to the acquisition, analysis, interpretation of data;
AND approved the submitted version; drafted the work and substantively revised it
AND has agreed both to be personally accountable for the author’s own contributions
and to ensure that questions related to the accuracy or integrity of any part of the work,
even ones in which the author was not personally involved, are appropriately
investigated, resolved, and the resolution documented in the literature. S.M.J. made
substantial contributions to the acquisition, analysis, interpretation of data; AND
approved the submitted version; AND has agreed both to be personally accountable for
the author’s own contributions and to ensure that questions related to the accuracy or
integrity of any part of the work, even ones in which the author was not personally
involved, are appropriately investigated, resolved, and the resolution documented in
the literature. J.L.W. and A.G.-H. made substantial contributions to the analysis,
interpretation of data; AND approved the submitted version; AND has agreed both to
be personally accountable for the author’s own contributions and to ensure that
questions related to the accuracy or integrity of any part of the work, even ones in
which the author was not personally involved, are appropriately investigated, resolved,
and the resolution documented in the literature. S.J.R. made substantial contributions to
the acquisition, analysis, interpretation of data; drafted the work and substantively
revised it AND approved the submitted version; AND has agreed both to be personally
accountable for the author’s own contributions and to ensure that questions related to
the accuracy or integrity of any part of the work, even ones in which the author was not
personally involved, are appropriately investigated, resolved, and the resolution
documented in the literature. Z.L. made substantial contributions to the analysis,
interpretation of data; AND approved the submitted version; AND has agreed both to
be personally accountable for the author’s own contributions and to ensure that
questions related to the accuracy or integrity of any part of the work, even ones in
which the author was not personally involved, are appropriately investigated, resolved,
and the resolution documented in the literature. I.H. made substantial contributions to
the analysis, interpretation of data; drafted the work and substantively revised it AND
approved the submitted version; AND has agreed both to be personally accountable for
the author’s own contributions and to ensure that questions related to the accuracy or
integrity of any part of the work, even ones in which the author was not personally
involved, are appropriately investigated, resolved, and the resolution documented in
the literature. E.S. made substantial contributions to the design of the work,
interpretation of data; drafted the work and substantively revised it AND approved
the submitted version; AND has agreed both to be personally accountable for the
author’s own contributions and to ensure that questions related to the accuracy or
integrity of any part of the work, even ones in which the author was not personally
involved, are appropriately investigated, resolved, and the resolution documented in
the literature. W.E.G. made substantial contributions to the conception and design of
the work, the acquisition, analysis, interpretation of data; drafted the work and
substantively revised it AND approved the submitted version; AND has agreed both to

Published in partnership with the Breast Cancer Research Foundation

be personally accountable for the author’s own contributions and to ensure that
questions related to the accuracy or integrity of any part of the work, even ones in
which the author was not personally involved, are appropriately investigated, resolved,
and the resolution documented in the literature.

COMPETING INTERESTS
F.O.A. declares no competing non-ﬁnancial interests but the following competing
ﬁnancial interests from Astra Zeneca, Gilead, Biotheranostics, Athenex, QED, Cardinal
Health, Teladoc Health, Pﬁzer, and research grants to her institution from Pﬁzer,
Seattle Genetics, Immunomedics, NeoImmuneTech, RNA Diagnostics, Astellas. F.G.,
C.R.S., I.C. and D.W.N. declare no competing ﬁnancial or non-ﬁnancial interests. R.W.
declares competing ﬁnancial interests from Seagen and declares competing nonﬁnancial interests as a scientiﬁc steering committee member for Celcuity. M.A.
declares no competing ﬁnancial or non-ﬁnancial interests. A.B. declares no
competing non-ﬁnancial interests but the following competing ﬁnancial interests
from Roche, Pﬁzer, Astra Zeneca, and Merck. C.D. declares no competing ﬁnancial or
non-ﬁnancial interests. C.A.S.-M. declares no competing non-ﬁnancial interests but
the following competing ﬁnancial interests from Seattle Genetics, Genomic Health,
Athenex, Polyphor, Halozyme, and research grants to his institution from
Astrazeneca, Pﬁzer, Novartis, Tesaro/GSK. R.M.C. declares no competing nonﬁnancial interests but the following competing ﬁnancial interests as research grants
to her institution from Novartis, Puma Biotechnology, Merck, Genentech, and
Macrogenics. J.F. declares no competing non-ﬁnancial interests but the following
competing ﬁnancial interests from Genomic Health, and ownership interests in
Genomic Health, and Immunomedics. A.M.-A. declares no competing non-ﬁnancial
interests but the following competing ﬁnancial interests as research grants to his
institution from Genentech, GSK. J.M.H., M.C., S.R.D., S.L., K.L.P., S.M.J., J.L.W., A.G.-H.,
S.J.R., Z.L., I.H., E.S. and W.E.G. declare no competing ﬁnancial or non-ﬁnancial
interests.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material
available at https://doi.org/10.1038/s41523-022-00500-3.
Correspondence and requests for materials should be addressed to Foluso O.
Ademuyiwa or William E. Gillanders.
Reprints and permission information is available at http://www.nature.com/
reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional afﬁliations.

Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://
creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022

npj Breast Cancer (2022) 134

